Fig. 2

CSF p-tau181 and t-tau according to AD Neuropathologic Scores Stratified according to other Pathology. (A) In a subgroup of patients with a low Braak NFT stage (≤II) at autopsy, antemortem CSF p-tau181 was slightly but significantly higher in patients with high amyloid pathologic scores compared with those with no amyloid pathology. (B) The difference in CSF t-tau between patients grouped by amyloid pathologic scores in a subgroup of patients with a low Braak NFT stage (≤II) was not significant. (C) Stratified according to the severity of amyloid pathology, CSF p-tau181 tended to be higher with a high Braak NFT stage (III) in patients with a low CERAD score and was significantly higher with a high Braak NFT stage (≥III) in patients with a high CERAD score. (D) In patients with a high CERAD score, CSF t-tau was significantly higher with high Braak NFT stages (≥V) at autopsy in patients only among those with a high CERAD score